Propanc Biopharma Inc (NASDAQ:PPCB) Short Interest Update

Propanc Biopharma Inc (NASDAQ:PPCB) saw a large decline in short interest in the month of June. As of June 30th, there was short interest totaling 16,903 shares, a decline of 95.2% from the June 15th total of 352,559 shares. Approximately 1.0% of the company’s shares are short sold. Based on an average daily trading volume, of 206,327 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Investors Weigh In On Propanc Biopharma

A hedge fund recently bought a new position in Propanc Biopharma stock. Virtu Financial LLC purchased a new position in shares of Propanc Biopharma Inc (NASDAQ:PPCB) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned approximately 0.33% of Propanc Biopharma as of its most recent SEC filing.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Propanc Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Propanc Biopharma Price Performance

PPCB stock traded down $0.17 during trading hours on Friday, reaching $1.61. 218,210 shares of the stock were exchanged, compared to its average volume of 3,139,218. The firm’s 50-day moving average is $1.82 and its 200-day moving average is $4.54. Propanc Biopharma has a 12 month low of $1.30 and a 12 month high of $270.25. The company has a market cap of $3.67 million, a price-to-earnings ratio of -0.07 and a beta of 3.49.

Propanc Biopharma declared that its board has initiated a share buyback program on Thursday, June 11th that permits the company to buyback $5.00 million in shares. This buyback authorization permits the company to repurchase up to 162.3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board believes its shares are undervalued.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.